Scott Schliebner MPH

Scott Schliebner, MPH, Vice President, Scientific Affairs - Rare Diseases, is a clinical strategist with a 20+ year background in clinical development specializing in rare diseases and orphan drug development. His breadth of experience encompasses all trial phases; a broad variety of study designs; interventional and observational studies; involving small molecules, biologics, gene therapies, and enzyme replacement therapies. His therapeutic expertise focuses on rare tumors, rare hematologic disorders, neuromuscular diseases, inborn errors of metabolism, and lysosomal storage disorders. Mr. Schliebner provides strategic and scientific consultation aimed at accelerating the development of orphan drugs and bringing new therapies to rare disease patients faster.

Mr. Schliebner has served in leadership roles across the biotech, non-profit, and CRO settings, with a focus on innovative approaches to accelerate rare disease clinical development. He has developed close working relationships with several rare disease research consortia, patient advocacy organizations, study research groups, and key opinion leaders. He is regularly asked to speak on patient-centric approaches, leveraging medical informatics, and new strategies to develop rare diseases therapies in emerging markets. He is a member of the DIA Rare Disease Planning Committee, holds an MPH degree from the University of Utah, School of Medicine, and completed a Graduate Research Fellowship at the NIH.